50 results about "Aminosugar" patented technology

A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

Compositions and methods relating to partially hydrolyzed fucoidan for use in dietary supplements and skin-care products are described. Fucoidan from brown seaweeds is partially hydrolyzed and/or sulfonated and then mixed with other ingredients for use as a dietary supplement in beverage, capsule, or tablet form or for use as a skin-care product. Other ingredients that can be included in the dietary supplements include vitamins, minerals, amino acids, carotenoids, flavonoids, antioxidants, aminosugars, glycosaminoglycans, and botanicals. Skin care products according to the present invention comprise partially hydrolyzed fucoidan and a base.

The present invention relates to treating joint related conditions in mammals by administering an aminosugar, and wherein said treatment specifically prevents, lessens or reverses pathologies associated with the joint condition, said pathologies being selected from the group consisting of synovitis, subchondral bone edema, and cartilage degradation.

The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

The present invention relates to compositions for the modulation of inflammation in connective tissues in humans and animals and the modulation of markers of such inflammation, including COX-2, TNF-α, IL-1β, iNOS, p38, and chemokines, comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothioneine, methylsulfanylmethane, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

The invention relates to combinations of an aminosugar and a beta-2-adrenoceptor agonist, such as salbutamol, for the treatment of diseases associated with hypersensivity and inflamation, in particular hypersensivity skin diseases. The aminosugar is preferably a monosaccharide derivative.

A process for preparing compounds of chitosan saccharified with aminosugar, adopts chitosan derivatives, aminosugar derivatives and anhydride derivatives as raw materials to synthesize target products. The process comprises: covalently bonding an anhydride derivative as a bonding arm to an aminosugar derivative, so as to form a monosaccharide derivative having an end group of carboxyl; and then covalently bonding the monosaccharide derivative having an end group of carboxyl to a primary amino group of a chitosan derivative via the carboxyl, so as to form a compound of chitosan saccharified with aminosugar.

The present disclosure relates to a chitosan solution neutralized with amino-sugar carbonate buffering solution or amino-sugar phosphate buffering solution or phosphorylated aminosugar buffering solution. The resulting thermogelling chitosan composition is highly biocompatible, isotonic and has the ability to rapidly turn into gel upon heating to the body temperature. It provides a novel chitosan-based composition to suitable for drug delivery, cell delivery and repair or regeneration of tissues and organs as well as other clinical treatment.

The invention discloses a pharmaceutical composition for curing chronic nasosinusitis and a preparation method thereof. The pharmaceutical composition contains phlegm-resolving prescription ambroxol hydrochloride and antibiotics which is one of Beta- lactam, aminoglycoside, macrolide, carbostyril, anti-anaerobe and lincomycin, or mixture of one of the antibiotics except the anti-anaerobe and the anti-anaerobe. The composition adopts a sinuses irrigation method to administrate and has the characteristics of convenient use, good validity, high safety and hard recurrence for the cure of the acute nasosinusitis and the chronic nasosinusitis.

An embodiment of the invention provides a composition having one or more active ingredients such as an aminosugar, more particularly, glucosamine, glucosamine salt, and mixtures thereof, and a glycosaminoglycan, more particularly, chondroitin, chondroitin salts, and mixtures thereof having a therapeutic use and is stable for at least 24 months. Additionally, the composition includes a diluent, glidant, and lubricant. The invention also provides a method of treating a connective tissue disease, injury, or condition comprising administering to a mammal any one of the compositions described herein. The composition can be in tablet or capsule form.

The invention relates to the field of medicinal chemistry, an aminosugar derivate, a preparation method and a medical application thereof, in particular to a compound N-(1, 3, 4, 6-fourth-O-galloylhyperin acetyl-2-deoxidizing-beta D-pyranoid galactosyl)-3-(2,4-dichlorophenyl)-acrylamide (I). Pharmacological experiments show that the compound (I) can inhibit the neovascularization of chick chorioallantoic membrane, therefore, the compound can be used for treating tumors or chronic inflammation clinically.

This invention provides a quantitative analysis of glycan biosynthesis along meta pathways using computer simulation for comparing a computer generated spectrum to experimental data to quantitatively track the biosynthesis. Computer simulating the mass spectra of isotopic detection of aminosugars with glutamine experiments allows modeling the glycan biosynthesis over time, via changes in the ¹⁴N and ¹⁵N isotope abundance levels, to estimate the relative abundance of molecules involved in glycan biosynthesis, from experimental mass spectra. Gradient search optimization is used to maximize the coefficient of determination between the experimental spectrum and the simulated spectrum. These relative abundances are then fed into a pathway simulation model to analyze glycan biosynthesis. Simulating a mass spectrum allows reconfirming the identification, quantifying the isotopic configurations and obtaining the relative abundance of each as samples are taken at periodic intervals, which is then organized to allow tracking the changes in abundance levels over time.

The invention discloses an application of an Htra2 gene expression inhibitor in prevention of acquired sensorineural deafness. The Htra2 gene expression inhibitor is used for preventing ototoxic deafness caused by aminoglycoside antibiotics. The invention also provides a CRISPR/Cas9 gene editing system for preventing the acquired sensorineural deafness, and the CRISPR/Cas9 gene editing system is used for targeting and knocking out the Htra2 gene. The invention proves that the AAV-CRISPR/Cas9-Htra2 gene editing system inner ear microinjection can be used for safely and effectively preventing the ototoxic deafness caused by the aminoglycoside antibiotics.

The invention discloses a reversible phase change atomized liquid gel containing a hydrocarbyl-amino-glycosyl three-stage glycosyl gelling agent, which comprises the following components in percentageby mass: 0.1-3.0 wt% of a glycosyl gelling agent and 97.0-99.9 wt% of atomized liquid. The chemical structural formula of the glycosyl gelling agent is shown in the specification, wherein R1 and R2 are hydrocarbyl. The atomized liquid gel disclosed by the invention has a thermal reversible phase change characteristic and/or a shear reversible phase change characteristic, the gel-sol phase changetemperature is 135-160 DEG C, and the gel-sol phase change critical shear stress is 55-330Pa. Under heating and/or oscillation, the atomized liquid gel is changed into a sol state from a gel state, and an atomizing agent fixed in the gel is released to form inhalable aerosol; and when heating and/or oscillation is stopped, the sol-state gel rapidly recovers to a gel state, and the atomizing agentwhich is not atomized in the gel is fixed in the gel network again. The atomized liquid gel disclosed by the invention can solve the problem of smoke condensate after suction is stopped and the problem of smoke liquid leakage of an atomizer caused by air pressure change or external force action in transportation.

Formula IA, and their use for treating viral infections.